McNeil Sales Still Slowed By Pseudoephedrine Limits
This article was originally published in The Tan Sheet
Executive Summary
Pseudoephedrine restrictions were the primary driver behind a 7% decline in first-quarter U.S. sales for Johnson & Johnson's McNeil Consumer division, J&J reported during an April 18 earnings call
You may also be interested in...
J&J sales
McNeil Consumer & Specialty Pharmaceuticals "will maintain a limited number of products containing pseudoephedrine for behind the counter sale" but "is in the process of reformulating our products that contain this ingredient," J&J VP- Investor Relations Helen Short stated during a third-quarter earnings call Oct. 18. The "negative impact" of restrictions implemented on products containing pseudoephedrine was responsible for offsetting sales growth for the McNeil division during the third quarter, Short added. The McNeil franchise had operational growth of 11% for the third quarter, six points of which were a result of a reclassification of certain OTC products from the pharmaceutical division to McNeil in January, Short said. Imodium, Pepcid and Motilium were among those reclassified (1"The Tan Sheet" July 25, 2005, p. 10). Global consumer sales of $2.2 bil. for the quarter represented an increase of 10.2% over the prior-year period, the firm said...
Judge Orders FDA, Food Safety Group To Set FSMA Implementation Date
FDA’s delays in implementing the Food Safety Modernization Act violated FSMA and the Administrative Procedures Act, a federal court finds in an April 22 order. The agency must meet with plaintiff Center for Food Safety to agree on new implementation deadlines by May 20.
Judge Orders FDA, Food Safety Group To Set FSMA Implementation Date
FDA’s delays in implementing the Food Safety Modernization Act violated FSMA and the Administrative Procedures Act, a federal court finds in an April 22 order. The agency must meet with plaintiff Center for Food Safety to agree on new implementation deadlines by May 20.